Legend Capital was among the participants as Rec-Biotechnology raised series B funding that will be used for clinical trials of its vaccine candidates.
China-based vaccine developer Rec-Biotechnology secured more than RMB1.5bn ($227m) yesterday in a series B round featuring Legend Holdings, the venture capital firm formed by conglomerate Legend Holdings, DealStreetAsia reported.
Lyfe Capital, Sequoia Capital China, Vertex Ventures China, Haitong Securities subsidiary HT Capital, Co-Stone Asset Management, YuanBio Venture Capital, Tsing Song Capital and China Everbright also took part, according to a WeChat post by financial adviser Life Venture.
Founded in 2012 and also known as Abzymo Biosciences, RecBio is working on…
